<DOC>
	<DOCNO>NCT02028494</DOCNO>
	<brief_summary>The purpose study compare efficacy novel schedule oral anticancer drug , capecitabine , patient metastatic breast cancer . Mathematical model predict 7 day capecitabine follow 7 day rest optimal dose schedule drug previous study do al Memorial Sloan Kettering Cancer Center support tolerability scheme . This definitive , randomized trial compare efficacy new dosage conventional dosing schedule patient metastatic breast cancer necessary hypothesize superior term efficacy . Dosing schedule base mathematical prediction optimal drug delivery base efficacy rather toxicity could facilitate rapid economical drug development . This trial proof principle trial high priority .</brief_summary>
	<brief_title>Evaluation Response Two Schedules Capecitabine Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 Subject Inclusion Criteria Informed consent obtain . Metastatic breast cancer . Measurable nonmeasurable disease per RECIST criterion . Pathologic confirmation breast cancer . No limit number prior chemotherapy regimen permit metastatic disease . At least 3 week since prior chemotherapy . Patients recover acute toxicity therapy ( exclude alopecia ) . Age ≥18 . ECOG 02 Absolute Neutrophil Count ( ANC ) ≥1.0 ; hemoglobin ≥9 , platelet ≥75.000 AST , ALT Alkaline phosphatase &lt; 2.5x upper limit normal ( &lt; 5x upper limit normal case liver metastasis ) . Total bilirubin &lt; 1.5x upper limit normal . Estimated creatinine clearance &gt; 50ml/min . If female childbearing potential , pregnancy test negative patient agree use effective method avoid pregnancy study . HER2 overexpression and/or amplification determine immunohistochemistry ( 3+ ) FISH ( &gt; 2.0 ) . No prior fluoropyrimidine metastatic setting . Adjuvant fluoropyrimidine permit &gt; 12 month elapse since treatment . No restriction prior hormonal therapy . GI malabsorption syndrome could impair oral drug absorption . Concurrent use warfarin discourage drug interaction may make management INR difficult . Central nervous system metastasis permit previously treat clinically stable least 3 month . Pregnant nursing patient . Life expectancy &lt; 3 month .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>